MWNA
RXDX

Marshall Wace North America’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Marshall Wace North America’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-79,171
Closed -$1.45M – 1892
2021
Q1 		$1.45M Buy
+79,171
New +$1.63M 0.01% 917

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Marshall Wace North America's RXDX Position: Q2 2021 in Review

Marshall Wace North America sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2021, closing a stake of 79,171 shares — an estimated $1.45M sold.

Marshall Wace North America first reported a position in RXDX in Q1 2021 and held it in 1 quarter. The position peaked at $1.45M in Q1 2021. 49 funds tracked by Wall St. Rank hold RXDX as of Q2 2021.

  • Marshall Wace North America reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 79,171 Prometheus Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $1.45M.
  • Marshall Wace North America first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Prometheus Biosciences, Inc. Common Stock position peaked at $1.45M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.